Inclusion Criteria:

          1. Regimen A only (monotherapy): Subjects with advanced metastatic solid tumors

          2. Regimen B only (combination with trastuzumab): Subjects with advanced metastatic HER2+
             solid tumors

          3. Regimen C only (combination with cetuximab): Subjects with advanced metastatic EGFR+
             solid tumors

          4. Available related donor who is CMV+ and HLA-haploidentical or better but not fully
             HLA-matched

          5. Presence of measurable disease by RECIST 1.1

          6. Life expectancy of at least 3 months.

          7. Provision of signed and dated informed consent form (ICF).

          8. Stated willingness to comply with study procedures and duration.

        Exclusion Criteria:

          1. Females of reproductive potential that are pregnant or lactating, and males or females
             not willing to use a highly effective form of contraception from Screening through the
             end of the study.

          2. Eastern Cooperative Oncology Group (ECOG) performance status >2.

          3. Evidence of insufficient organ function as determined by the protocol.

          4. Receipt of any biological therapy, chemotherapy, or radiation within 1 week of the
             Screening Visit and at least 3 weeks prior to Day 1, except for patients receiving
             maintenance trastuzumab.

          5. Have central nervous system disease (CNS) as follows:

               1. Dose Escalation Cohorts: Active CNS disease, including history of CNS metastases.

               2. MTD/MFD Expansion Cohorts: CNS disease, including history of CNS metastases, that
                  was not stable during the last 6 months.

          6. Myocardial infarction (MI) within 6 months of Screening Visit.

          7. Severe asthma.

          8. Currently receiving or likely to require systemic immunosuppressive therapy from Day
             -7 to Day 29.

          9. Uncontrolled infections.

         10. Presence of any medical or social issues that are likely to interfere with study
             conduct, or may cause increased risk to subject.